News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If they "forgot" to file those forms, what else have they "forgotten" to tell investors?
Champignon Brands Served a Cease Trade Order
https://psilocybinalpha.com/news/champignon-brands-served-a-cease-trade-order
Probably a MM bought them to sell 'em back next week @ .55.
Waiting till it hits a quarter?
Good thing - looks like shareholders will have to eat gumballs for breakfast lunch & dinner for the foreseeable future.
I hear purple ones are the healthiest. 
Unfounded optimism isn't evidence of progress.
And neither are PR's in pinkyland - most are bogus.
Even financials are suspect UNTIL INDEPENDENTLY VERIFIED.
The frenzy which caused impetuous investors to throw buckets of money at a brand new stock with no revenue primarily because of a famous investor, appears to have worn out like a 1¢ gumball.
Top 10 Marijuana and Psychedelic Stock News Stories of the Week
News Stories Here <---Click HERE
Getting mauled by bears isn't as fun as it sounds.
Might dip my toe in here, loving the bearish feel
Wonder who thought up Apotheosis Scientific Ltd.
That would be an asinine name for a fledgling company.
apotheosis
noun
the highest point in the development of something; culmination or climax: his appearance as Hamlet was the apotheosis of his career.
• the elevation of someone to divine status; deification.
LOL
The Company also announces that it plans to change its name from Champignon Brands Inc. to Apotheosis Scientific Ltd., or such other name as the Company’s directors may determine to better reflect the Company’s business activities going forward.
As the Man In Black used to sing...
I like BK
Haven't had the Halloween Whopper yet.
The problem with this stock is... it's too damn cheap!
It gives off the perception of being tawdry and tacky.
People hate buying cheap shit - that's why they'll spend hundreds on sneakers.
See - last month when the price was double what it is now, people thought it was kewl and they had to have it...and the volume spiked accordingly.
Then the price fell and no one wanted to be seen in it anymore - like Payless shoes.
I've discovered that the "bottom" in OTC is NEVER the bottom.
At least not until they hit .000001 - I haven't seen one go lower.
It's not fun looking for the bottom.
Ya might want to change your sig DJ, because shroom stocks ain't lookin' so good either.
This one's down over 52% from 3 weeks ago, and MindMed's down 97% since January.
That's a really bad trip for investors!
Some canabis stocks have been recovering lately - helped by the quarantine.
|
Followers
|
38
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
662
|
|
Created
|
03/02/20
|
Type
|
Free
|
| Moderators | |||
Patents are the lifeblood of the biotech industry. Biotechnology is one of the most research-intensive industries, with companies in the sector typically investing between 40% and 50% of their revenues in research and development, compared to 13% in pharmaceuticals and 5% in the chemical industry. In many cases, IP rights can actually be the final product.
That's why Champignon Brands' ( SHRM ; SHRMF ) already impressive cache of pharmaceutical patents gives it a leg up in the competitive rush to claim market share in the nascent Psilocybin industry.
Normally, when you do clinical trials, the ideal is to own the resulting IP. Champignon is partnering with the University of Miami and Miller School of Medicine in its research work but will own 100% of the intellectual property, drug discovery, and resultant data.
Its Psilocybin Patent Portfolio will greatly help the company in the commercialization of GMO and vegan certified rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Even better: It can license its patented formulations to other companies as it deems fit.
Canada NewsWire
VANCOUVER, BC, Oct. 29, 2020
VANCOUVER, BC, Oct. 29, 2020 /CNW/ - Champignon Brands Inc. ("Champignon" or the "Company") (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) continues to work diligently with the British Columbia Securities Commission (the "Commission") to address the ongoing continuous disclosure review and to coordinate the revocation of the existing cease trade order. The Company will provide guidance on definitive timing for revocation as soon as possible.
The Company has submitted all requested documentation to the Commission in connection with the review of financial statements of AltMed Capital Corp. ("AltMed") for the period ended June 30, 2020, and subject to review by the Commission expects to move forward with the finalization and public filing of these statements in short order.
Continuous Disclosure Review History
On June 19, 2020, the Company was notified by the Commission that it would be subject to a continuous disclosure review. Such reviews are conducted by the Commission for the purposes of ensuring compliance with the continuous disclosure obligations imposed by applicable Canadian securities laws. In the case of the Company, this review relates to the Company's disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding acquisitions completed by the Company since that time.
In connection with the review, on June 19, 2020, the Commission issued a cease trade order suspending trading in the securities of the Company pending the filing of Business Acquisition Reports in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. As a result of the cease trade order, trading in the common shares of the Company was suspended on the Canadian Securities Exchange.
The Business Acquisition Reports were filed by the Company on July 21, 2020, during which time the Company continued to work with the Commission to address comments received in the course of the disclosure review. As a result of the filing of the Business Acquisition Reports, on August 26, 2020, the Commission revoked the cease trade order previously issued on June 19, 2020. Concurrently with the revocation, the Commission issued a replacement cease trade order (the "Replacement Order"), pending the filing of a revised material change report (the "Material Change Report") in connection with the acquisition by the Company of AltMed.
Prior to the finalization of a revised Material Change Report, the Company is required to finalize the accounting treatment for the acquisition of AltMed, which includes compiling the financial statements of AltMed for the six-month period ended June 30, 2020 to meet disclosure requirements.
On October 27, 2020, the Commission issued an additional cease trade order pending the filing of the interim financial statements of the Company for the period ended June 30, 2020 (the "October Order").
The October Order is not expected to affect the review process or timing for the resumption of trading of the common shares of the Company as the reports required to be filed to satisfy the Replacement Order will address the outstanding items in the October Order.
For further clarity, the Company anticipates that the Replacement Order and the October Order will be revoked at the same time. The Company is working diligently with the Commission to ensure that the revocation of both the Replacement Order and October Order occurs as soon as possible.
Dr. Roger McIntyre
Chief Executive Officer
E: info@champignonbrands.com
FOR INVESTOR INQUIRIES:
Champignon Brands | Storyboard Communications
Investor Relations, Toronto, Canada
Investor Line: +1 (833) 375-9995 x611
E: champignonbrands@storyboardcommunications.com
AI
